Nexalin Technology announced positive results from a clinical trial on DIFS technology for mild Alzheimer's disease, showing improvements in memory and cognitive function. The study demonstrated significant cognitive gains and increased neural activity in the hippocampus, offering promise as a drug-free treatment option.